A new vision in the fight against oral cancer has arrived
ESPýOC™ is a simple, cost effective and non-invasive chaired test that provides important screening information for patients with suspicious lesions. In university supervised clinical trials ESPýOC™ never failed to detect cancer and even detected
74% of precancer.
Early detection is your best fight against oral cancer. If detected before the cancer cells have spread and Stage 1 cancer has begun, you can increase your survival rate by up to 32%. Find it early.
Fight it early.
We’ve done the research so you don’t have to. In university supervised double-blinded clinical trials, ESPýOC™ had the lowest false positive and false negative rates of any oral cancer-screening product on the market today.
ESPýOC™ goes one step further than UV autofluoresence by adding a liquid solution to the detection process. ESPýOC™ highlights oral cancer by recognizing cells’ increased density of nucleic DNA and presence of carbohydrate chains.
Dental offices examine oral cavities more than any other profession and patients rely on them for health inspection beyond just teeth. ESPýOC™ has given dental professionals a way to confidently refer patients on to oral specialists.
The proof is in the numbers. When placed side-by-side with the industry’s leading competitors, ESPýOC™ out performed each of them. You can’t argue with 74% detection of precancer and 100% detection of oral cancer.